BeiGene, Ltd. announced that BRUKINSA® (zanubrutinib) has received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.
[BeiGene, Ltd.]
7992332
nan
items
1
apa
0
default
asc
1
166857
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
